Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “antagonist”

678 pharma patents match "antagonist" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 678
Index total 30,257
Page 14 / 29

Quick answer

This filtered view shows 678 pharmaceutical patents matching "antagonist" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

678 results for “antagonist” · 30,257 patents in full index Clear search

  1. US 9089555

    Complement antagonists and uses thereof

    REGENESANCE B.V. · Granted Jul 28, 2015 · Expires Jul 23, 2035

    granted

  2. US 9090573

    Compounds as lysophosphatidic acid receptor antagonists

    AMIRA PHARMACEUTICALS, INC. · Granted Jul 28, 2015 · Expires Jul 23, 2035

    granted

  3. US 9084773

    Small molecule antagonists of bacterial quorum-sensing receptors

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Jul 21, 2015 · Expires Jul 16, 2035

    granted

  4. US 9079913

    Spiro-oxindole MDM2 antagonists

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jul 14, 2015 · Expires Jul 9, 2035

    granted

  5. US 9012447

    5-HT3 receptor antagonists

    Takeda Pharmaceutical Company Limited · Granted Apr 21, 2015 · Expires Apr 16, 2035

    granted

  6. US 9000173

    Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity

    Theravance Respiratory Company, LLC · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted

  7. US 8980855

    Minor groove binder (MGB)-oligonucleotide miRNA antagonists

    Elitech Holding B.V. · Granted Mar 17, 2015 · Expires Mar 12, 2035

    granted

  8. US 8969292

    High affinity leptins and leptin antagonists

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Mar 3, 2015 · Expires Feb 26, 2035

    granted

  9. US 8969370

    3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Mar 3, 2015 · Expires Feb 26, 2035

    granted

  10. US 8952161

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Neurocrine Biosciences, Inc. · Granted Feb 10, 2015 · Expires Feb 5, 2035

    granted

  11. US 8952031

    Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Feb 10, 2015 · Expires Feb 5, 2035

    granted

  12. US 8927573

    8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Jan 6, 2015 · Expires Jan 1, 2035

    granted

  13. US 8921348

    Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  14. US 8921316

    Stable liquid VEGF antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  15. US 8916570

    A3 adenosine receptor agonists and antagonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  16. US 8912334

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Dec 16, 2014 · Expires Dec 11, 2034

    granted

  17. US 8901141

    Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them

    Takeda Pharmaceutical Company Limited · Granted Dec 2, 2014 · Expires Nov 27, 2034

    granted

  18. US 8895579

    Heterotricyclic AMPA receptor antagonists for treatment of epilepsy, pain, and other neurological disorders and diseases

    Northwestern University · Granted Nov 25, 2014 · Expires Nov 20, 2034

    granted

  19. US 8895755

    Intermediates for preparing dual-acting benzyl triazole antihypertensive agents having angiotensin II type I receptor antagonist activity and neprilysin-inhibition activity

    Theravance Biopharma R&D IP, LLC · Granted Nov 25, 2014 · Expires Nov 20, 2034

    granted

  20. US 8889133

    Methods of treating diabetes with Dll4 antagonists

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 18, 2014 · Expires Nov 13, 2034

    granted

  21. US 8883214

    Implantable delivery vehicle for ocular delivery of muscarinic antagonists

    The Regents of the University of California · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted

  22. US 8877796

    Spiro-oxindole MDM2 antagonists

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 4, 2014 · Expires Oct 30, 2034

    granted

  23. US 8853252

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Oct 7, 2014 · Expires Oct 2, 2034

    granted

  24. US 8840886

    Method of treating cancer with DLL4 antagonist and chemotherapeutic agent

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 23, 2014 · Expires Sep 18, 2034

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.